Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. (NASDAQ: OCGN) regularly issues news updates about its progress in gene therapies for blindness diseases, making its news flow particularly relevant for investors and observers of the ophthalmic biotechnology space. The company’s announcements often cover clinical trial milestones, licensing agreements, financing transactions, and participation in industry and investor conferences.
A major focus of Ocugen’s recent news has been its modifier gene therapy platform and associated programs. Updates include Phase 1, Phase 2, and Phase 2/3 data for investigational products such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease. Press releases describe safety and exploratory efficacy findings, such as lesion growth reduction and visual function outcomes, as well as plans for future regulatory submissions.
Ocugen’s news stream also highlights business development and capital markets activity. Examples include an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for OCU400 in the Republic of Korea, registered direct offerings of common stock and warrants, and updates on cash runway and financial results. In addition, the company frequently announces webcasts and conference calls to discuss quarterly results, business updates, and key clinical data readouts.
Another recurring theme in Ocugen’s news is its presence at healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference, NobleCon, and rare disease–focused events. These items outline presentation topics, panel participation, and the company’s messaging around its goal of advancing multiple Biologics License Application (BLA) filings within a defined timeframe.
Investors and followers of OCGN news can use this page to monitor clinical trial progress, licensing developments, financing events, and strategic communications as Ocugen advances its gene therapy programs for major retinal diseases.
Ocugen has expanded its agreement with Bharat Biotech to include the commercialization of COVAXIN™ in Mexico, granting it rights across North America. The vaccine is already authorized for emergency use in adults in Mexico and is under review for children aged 2-18. Dr. Shankar Musunuri, Ocugen's CEO, expressed optimism about the vaccine's role in combatting COVID-19 in Mexico. COVAXIN™ is noted for its robust immune response and logistical advantages. The agreement retains the same profit-sharing structure as in the U.S.
Ocugen announced that the FDA placed its Phase 2/3 immuno-bridging study for COVAXIN™ on clinical hold due to a voluntary pause in dosing participants. This decision follows the World Health Organization’s inspection of Bharat Biotech's manufacturing facility. The company aims to address the FDA's questions while evaluating these findings. Ocugen remains focused on advancing its innovative therapies and will collaborate with the FDA to resolve the clinical hold for OCU-002.
Ocugen, a biotechnology company, has commenced the Phase 1/2 clinical trial of OCU400 for treating retinitis pigmentosa (RP), marking its first clinical trial in humans for its modifier gene therapy platform. The first patient has been dosed in this observer-blind trial, which aims to evaluate safety and efficacy. RP, affecting approximately two million people globally, currently has no approved therapies. The trial focuses on genetic mutations in the NR2E3 and RHO genes, with potential future expansions to target more mutations.
Ocugen, Inc. (NASDAQ: OCGN) has appointed Dr. Marna C. Whittington to its Board of Directors, effective March 21, 2022. Dr. Whittington, a seasoned financial leader, previously served as CEO of Allianz Global Investors Capital and has held positions at Morgan Stanley and the University of Pennsylvania. Her expertise is expected to bolster Ocugen's growth strategy concerning its gene therapies and vaccine candidates. The announcement follows the departure of Manish Potti, who did not seek reappointment, expressing confidence in the company's future in addressing unmet medical needs.
Ocugen, Inc. (NASDAQ: OCGN) announced the appointment of Jessica Crespo as Chief Accounting Officer and Senior Vice President, Finance, effective March 18, 2022. With over 20 years of experience, Crespo previously served as Vice President, Corporate Controller, and Treasurer at Ocugen. Her responsibilities include financial strategy development and oversight of accounting and reporting functions. Chairman Dr. Shankar Musunuri emphasized her valuable contributions, crucial to sustaining the company’s growth as it advances therapies toward regulatory approval.
Ocugen announced on March 18, 2022, that its Board of Directors approved stock options for 331,155 shares and restricted stock units (RSUs) for 90,232 shares to nine new hires. The stock options, with a ten-year term, have an exercise price of $2.87 per share, aligning with the closing price on the grant date (March 16, 2022). Both options and RSUs will vest annually over three years, contingent on continued employment. This grant supports Ocugen's focus on gene therapies for blindness and COVID-19 vaccine development.
Ocugen, Inc. (NASDAQ: OCGN) announces that Dr. Shankar Musunuri, Chairman and CEO, will present at the 34th Annual Roth Conference on March 14, 2022, at 11:00 AM PT in Dana Point, CA. The event will feature meetings, analyst chats, and industry panels from approximately 400 companies. Ocugen focuses on gene therapies for retinal diseases and co-develops the COVID-19 vaccine candidate COVAXIN™. A live audio webcast of the presentation will be available on the company’s investor relations website.
Ocugen, Inc. (NASDAQ: OCGN) announced that the FDA has declined to issue an Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate, COVAXIN™, for individuals aged 2 to 18. The company plans to collaborate with the FDA to explore regulatory pathways for pediatric use. Ocugen is dedicated to developing gene therapies for blindness diseases and furthering its vaccine initiative. The ongoing efforts reflect Ocugen's commitment to advancing solutions in both ocular diseases and infectious diseases.
Ocugen reported significant progress in its COVAXIN™ development, with the FDA lifting the clinical hold on its IND application, enabling the commencement of Phase 2/3 trials. The company submitted a substantial safety database involving over 36 million vaccinated teens to support its pediatric EUA request. Additionally, Ocugen initiated a Phase 1/2 trial for its OCU400 gene therapy. Despite increased R&D and administrative expenses, cash reserves expanded to $95.1 million. The company announced a public offering of 16 million shares to further support its development pipeline.
Ocugen, Inc. (Nasdaq: OCGN) announced a public offering of approximately 15.97 million shares of common stock, priced for gross proceeds of about $53.5 million. The offering is set to close on or about February 25, 2022. An additional 2.39 million shares may be purchased by the underwriter within 30 days. Proceeds will be used for corporate purposes, including working capital. Cantor Fitzgerald & Co. is the sole book-running manager for this offering, which is conducted under a previously filed shelf registration with the SEC.